HLS Therapeutics (TSE:HLS) Trading 0.2% Higher – Here’s Why

HLS Therapeutics Inc. (TSE:HLS) was up 0.2% during trading on Tuesday . The company traded as high as C$4.71 and last traded at C$4.65. Approximately 7,500 shares changed hands during trading, a decline of 15% from the average daily volume of 8,815 shares. The stock had previously closed at C$4.64.

HLS Therapeutics Stock Up 0.2%

The firm has a market cap of C$145.42 million, a price-to-earnings ratio of -11.92 and a beta of 0.34. The business’s 50 day moving average price is C$4.46 and its 200 day moving average price is C$4.77. The company has a debt-to-equity ratio of 80.79, a quick ratio of 1.01 and a current ratio of 1.11.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings data on Thursday, March 12th. The company reported C($0.05) EPS for the quarter. The firm had revenue of C$20.06 million for the quarter. HLS Therapeutics had a negative return on equity of 19.40% and a negative net margin of 22.34%. On average, equities analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.